These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 12018776)

  • 21. Bayesian design and conduct of phase II single-arm clinical trials with binary outcomes: a tutorial.
    Zohar S; Teramukai S; Zhou Y
    Contemp Clin Trials; 2008 Jul; 29(4):608-16. PubMed ID: 18201945
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug costs: research and development costs: the great illusion.
    Prescrire Int; 2004 Feb; 13(69):32-6. PubMed ID: 15055226
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical development of anti-tuberculosis drugs.
    Mitchison DA
    J Antimicrob Chemother; 2006 Sep; 58(3):494-5. PubMed ID: 16840430
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical drug trials in Germany--an assessment of current status from the viewpoint of industry].
    Baumbauer E
    Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():646-50. PubMed ID: 9101960
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Health economics evaluations are of great significance for Pharmaceutical Benefit Board's decisions].
    Persson U; Ramsberg J
    Lakartidningen; 2007 Oct 17-23; 104(42):3046-50. PubMed ID: 17985712
    [No Abstract]   [Full Text] [Related]  

  • 26. A Bayesian approach for incorporating economic factors in sample size design for clinical trials of individual drugs and portfolios of drugs.
    Patel NR; Ankolekar S
    Stat Med; 2007 Nov; 26(27):4976-88. PubMed ID: 17579924
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Informing the selection of futility stopping thresholds: case study from a late-phase clinical trial.
    Hughes S; Cuffe RL; Lieftucht A; Garrett Nichols W
    Pharm Stat; 2009; 8(1):25-37. PubMed ID: 18383194
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A quantitative approach to benefit-risk assessment of medicines--part 1: the development of a new model using multi-criteria decision analysis; part 2: the practical application of a new model.
    Mussen F; Salek S; Walker S
    Pharmacoepidemiol Drug Saf; 2007 Jul; 16 Suppl 1():S42-6. PubMed ID: 17546572
    [No Abstract]   [Full Text] [Related]  

  • 29. A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trial.
    Bekele BN; Shen Y
    Biometrics; 2005 Jun; 61(2):343-54. PubMed ID: 16011680
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bayesian sample size calculations in phase II clinical trials using informative conjugate priors.
    Mayo MS; Gajewski BJ
    Control Clin Trials; 2004 Apr; 25(2):157-67. PubMed ID: 15020034
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The strategic interaction between firms and formulary committees: effects on the prices of new drugs.
    García-Alonso MD; García-Mariñoso B
    J Health Econ; 2008 Mar; 27(2):377-404. PubMed ID: 18276026
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selection of licensing candidates in the pharmaceutical industry: an application of the analytic hierarchy process.
    Ross ME; Nydick RL
    J Health Care Mark; 1992 Jun; 12(2):60-5. PubMed ID: 10119215
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decision analysis in forensic science.
    Taroni F; Bozza S; Aitken C
    J Forensic Sci; 2005 Jul; 50(4):894-905. PubMed ID: 16078494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. One-sided sequential stopping boundaries for clinical trials: a decision-theoretic approach.
    Berry DA; Ho CH
    Biometrics; 1988 Mar; 44(1):219-27. PubMed ID: 3358990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A decision theoretic approach to sample size determination in clinical trials.
    Gittins JC; Pezeshk H
    J Biopharm Stat; 2002 Nov; 12(4):535-51. PubMed ID: 12477073
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Value of information of a clinical prediction rule: informing the efficient use of healthcare and health research resources.
    Singh S; Nosyk B; Sun H; Christenson JM; Innes G; Anis AH
    Int J Technol Assess Health Care; 2008; 24(1):112-9. PubMed ID: 18218176
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A model for structured introduction of new drugs. The aim is to offer all patients appropriate treatment].
    Gustafsson LL; Wettermark B; Kalin M; Korkmaz S; Persson ME; Almkvist H; Hjemdahl P; Julander M; Kristianson K; Ringertz B; Bergen-Dahl GT; Wilking N
    Lakartidningen; 2008 Oct 15-21; 105(42):2917-22. PubMed ID: 19025148
    [No Abstract]   [Full Text] [Related]  

  • 38. Quantifying emerging drugs for very rare conditions.
    Miles KA; Packer C; Stevens A
    QJM; 2007 May; 100(5):291-5. PubMed ID: 17456610
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Bayesian decision support model for assessment of endodontic treatment outcome.
    Suebnukarn S; Rungcharoenporn N; Sangsuratham S
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Sep; 106(3):e48-58. PubMed ID: 18602284
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Missing steps in the STAIR case: a Translational Medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke.
    Feuerstein GZ; Zaleska MM; Krams M; Wang X; Day M; Rutkowski JL; Finklestein SP; Pangalos MN; Poole M; Stiles GL; Ruffolo RR; Walsh FL
    J Cereb Blood Flow Metab; 2008 Jan; 28(1):217-9. PubMed ID: 17579658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.